Syk inhibitor II, a pyrimidine-carboxamide analog, is a novel potent, cell-permeable, ATP-competitive inhibitor of Syk (Spleen tyrosine kinase) tyrosine kinase that selectively and reversibly inhibits Syk with IC50 of 41 nM.

BAY-61-3606 2HCl (BAY 61-3606, BAY 61-3606 dihydrochloride), cell-permeable imidazopyrimidine compound, is a potent and selective, oral, ATP-competitive, reversible inhibitor of Syk (Spleen tyrosine kinase) tyrosine kinase with immunomodulatory effects.

Gusacitinib (formerly known as EN-3351; ASN-002) is a novle and potent dual inhibitor of SYK/JAK (spleen tyrosine kinase/janus kinase) with antitumor activity in both hematological and solid tumor xenograft models.

Lanraplenib (also known as GS-9876; GS-SYK) is a highly selective and orally bioavailable Spleen Tyrosine Kinase (SYK) inhibitor with IC50 of 9.5 nM).

TAK-659 (TAK659) hydrochloride is a novel, potent, highly selective and orally bioavailable spleen tyrosine kinase (Syk) inhibitor (IC50 = 3.2 nM) with the potential for the treatment of chronic lymphocytic leukemia (CLL).

PRT-060318 3HCl (also known as PRT318 3HCl) is a novel, potent, selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.

R112 is a novel, potent and ATP-competitive inhibitor of Syk kinase with a Ki of 96 nM.

Fostamatinib disodium hexahydrate (formerly R-935788; R 935788; R-788; R788; trade name: Tavalisse) is the disodium salt and hexa-hydrated form of Fostamatinib which is a prodrug of the active metabolite R406.

BAY-61-3606 (BAY 61-3606, BAY 61-3606), cell-permeable imidazopyrimidine compound, is a potent and selective, oral, ATP-competitive, reversible inhibitor of Syk (Spleen tyrosine kinase) tyrosine kinase with Ki of 7.5 nM.

RO9021 (RO-9021) is a potent, orally bioavailavle, ATP-competative and selective inhibitor of spleen tyrosine kinase (SYK) with usefulness in autoimmune disease therapy, such as arthritis.